PHOTON BEAM THERAPY

FOR THE RELIEF OF PAIN AND DISCOMFORT OF ORAL MUCOSITIS

About CuraLase

CuraLase clinics have administered over 100,000 treatments to over 8,000 patients from 44 states and 31 countries, establishing an international reputation for exceptional patient care. Achieving over a 90% success rate, CuraLase offers a non-invasive treatment option to individuals with pain. CuraLase delivers a pathway for patients to “get their quality of life back.”

PATIENTS

TREATMENTS

SUCCESS

Why CuraLase?

The CuraLase crystal controlled frequency Photon Beam Therapy technology produces a monochromatic, coherent beam, which delivers the purest, most powerful and deepest penetrating source of energy to the cells. 

The results are relief of pain, decreasing inflamation, increasing circulation and accelerated healing.
The CuraLase Photon Beam Therapy delivers a unique wavelength which transports photons of energy to the deep tissue rather than being absorbed superficially. This enables the photons to reach the targeted tissue and stimulate the cellular process. The higher energy state (ATP) enables the cell to carry out it’s cellular function at an enhanced level.

The CuraLase History

Since its founding in 2005, CuraLase has been an innovator in non-invasive Photon Therapy treatment for a multitude of painful conditions. Roger Porter, inventor and engineer, was seeking an alternative treatment for a family member’s excruciating pain from rheumatoid arthritis when he met Frank G. McArthur, MD. Dr. McArthur had previously been the Medical Director of the Health South system rehabilitation hospitals. Working together, Porter and McArthur researched and developed an innovative device and initial protocols. In December 2005, the CuraLase device was FDA cleared as a non-significant risk for the treatment of pain. The FDA rated the CL1000 with the safest classification awarded to any treatment modality. The first clinic opened in March 2006 in Myrtle Beach, South Carolina. Porter and a team of seven physicians refined the initial treatment protocols and developed new treatment protocols with great success.

PHOTON BEAM THERAPY

For over a decade and a half, the developers of CuraLase have been refining this photon delivery technology, and have developed a device that provides a wavelength and delivery system that not only is matched specifically to the receptors at the cellular level, but also avoids absorption by water, fat and other soft tissue during the delivery process.

Photon Beam Therapy is the delivery of photons targeting a specific area of tissue. The effectiveness of photon therapy is proportionate to the dosage of energy delivered, the abundance of chromophores and intracellular molecular substrates that are capable of absorbing and responding to the photon stimulation in the targeted tissue.

When the photons are delivered with the appropriate parameters (wavelength and dosage) the energy is absorbed by the molecular substrates in the mitochondria. These substrates, known as chromophores, are integrated into the mitochondrial respiratory chain. The respiratory chain is subsequently stimulated to increase ATP production.

The result of the increased ATP production is tissue-specific and positive effects have been demonstrated. These include resolution of inflammation and increasing circulation which aids in wound healing and pain relief.

CuraLase was awarded FDA clearance in 2005.

CuraLase Medical Advisory Board

John Charles, MD, FACEP
LINK TO BIO
Praveen R Arany, BDS, MDS, MMSc, PhD
LINK TO BIO

CLINICAL TRIALS

PHOTON BEAM THERAPY
Harvard clinical trial proves PBM activates stem cells to regenerate tissue

Study Location:
Harvard School of Engineering and Applied Sciences (SEAS)
Author Information:
David J. Mooney, Praveen Arany, Ph.D., 

CONCLUSION:
Harvard’s groundbreaking new research in the use of PBM to stimulate stem cells to regrow tissue is generating interest and excitement throughout the medical community.

https://www.ncbi.nlm.nih.gov/pubmed/24871130https://www.seas.harvard.edu/news/2014/05/researchers-use-light-to-coax-stem-cells-to-repair-teeth
A systematic review and meta-analysis of the effect of PBM on chemotherapy-induced oral mucositis in pediatric and young patients

Study Location:
Department of Hematology and Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Author Information:
Holanda VM, Chavantes MC, Wu X, Anders.

CONCLUSION:
Therapeutic PBM also reduces the average severity of oral mucositis and oral pain.

https://www.ncbi.nlm.nih.gov/pubmed/29128883
Efficacy of PMB for treatment of cancer oral mucositis

Study Location:
Graduation Program on Evaluation and Production of Technologies for the Brazilian National Health System, Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande do Sul, Brazil
Author Information:
Anschau F, Webster J, Capra MEZ, de Azeredo da Silva ALF, Stein AT.

CONCLUSION:
PBM demonstrates potential for decreasing the resolution time of OM lesions by approximately 4.21 days.

https://www.ncbi.nlm.nih.gov/pubmed/30729351
PBM in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial.

Study Location:
Département de Radiothérapie, Institut de Cancérologie de l’Ouest – Paul Papin, 15 rue André Boquel, Angers, France
Author Information:
Legouté F, Bensadoun RJ, Seegers V, Pointreau Y, Caron D, Lang P6, Prévost A, Martin L, Schick U, Morvant B, Capitain O, Calais G, Jadaud E.

CONCLUSION:
PBM was well tolerated with a good safety profile, which promotes its use in clinical routine for severe OM treatment.

https://www.ncbi.nlm.nih.gov/pubmed/31118057

Contact CuraLase

info@curalase.com

+1-843-716-5300